MCID: AVN001
MIFTS: 52

Avian Influenza malady

Categories: Rare diseases, Infectious diseases, Respiratory diseases

Aliases & Classifications for Avian Influenza

About this section

Aliases & Descriptions for Avian Influenza:

Name: Avian Influenza 10 12 51 2
Bird Flu 10 35 2
Influenza in Birds 36 65
 
H5n1 Influenza 51
Avian Flu 10

Classifications:



External Ids:

Disease Ontology10 DOID:4492
ICD1027 J09.X
SNOMED-CT59 55604004
MeSH36 D005585
Orphanet51 454836
UMLS65 C0016627

Summaries for Avian Influenza

About this section
MedlinePlus:35 Birds, just like people, get the flu. bird flu viruses infect birds, including chickens, other poultry, and wild birds such as ducks. most bird flu viruses can only infect other birds. however, bird flu can pose health risks to people. the first case of a bird flu virus infecting a person directly, h5n1, was in hong kong in 1997. since then, the bird flu virus has spread to birds in countries in asia, africa, the middle east, and europe. human infection is still very rare, but the virus that causes the infection in birds might change, or mutate, to more easily infect humans. this could lead to a pandemic, a worldwide outbreak of the illness. during an outbreak of bird flu, people who have contact with infected birds can become sick. it may also be possible to catch bird flu by eating poultry or eggs that are not well cooked or through contact with a person who has it. bird flu can make people very sick or even cause death. antiviral medicines may make the illness less severe, and may help prevent the flu in people who were exposed to it. there is currently no vaccine.

MalaCards based summary: Avian Influenza, also known as bird flu, is related to influenza and newcastle disease, and has symptoms including fever, cough and sore throat. An important gene associated with Avian Influenza is FURIN (Furin, Paired Basic Amino Acid Cleaving Enzyme), and among its related pathways are NGF processing and Influenza A. Affiliated tissues include respiratory tract of humans, lung and testes, and related mouse phenotypes are digestive/alimentary and respiratory system.

Disease Ontology:10 An influenza that results in infection located in respiratory tract of humans, domestic and wild birds, has material basis in Influenza A virus, which is transmitted by contact with infected poultry. Five strains of avian influenza A viruses (H5N1, H7N3, H7N2, H7N7 and H9N2) are known to cause human infections. The infection has symptom fever, has symptom cough, has symptom sore throat, has symptom muscle aches, has symptom nausea, has symptom diarrhea, has symptom vomiting, has symptom neurologic changes, has symptom pneumonia, and has symptom acute respiratory distress.

CDC:2 More

Wikipedia:68 Avian influenza — known informally as avian flu or bird flu — refers to \"influenza caused by... more...

Related Diseases for Avian Influenza

About this section

Graphical network of the top 20 diseases related to Avian Influenza:



Diseases related to avian influenza

Symptoms for Avian Influenza

About this section

Symptoms:

 10 (show all 10)
  • fever
  • cough
  • sore throat
  • muscle aches
  • nausea
  • diarrhea
  • vomiting
  • neurologic changes
  • pneumonia
  • acute respiratory distress

UMLS symptoms related to Avian Influenza:


snoring, pruritus, coughing

Drugs & Therapeutics for Avian Influenza

About this section

Drugs for Avian Influenza (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 118483
2VaccinesPhase 4, Phase 3, Phase 2, Phase 16085
3
Aluminum hydroxideapprovedPhase 2, Phase 3, Phase 1178
Synonyms:
Al(OH)3
Aluminiumhydroxid
 
Aluminum Hydroxide
Aluminum hydroxide
Dermadrox
4
OseltamivirapprovedPhase 2, Phase 3, Phase 193204255-11-865028
Synonyms:
(-)-Oseltamivir
(-)-oseltamivir
(3R,4R,5S)-4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid
(3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acid
(−)-oseltamivir
196618-13-0
204255-11-8
4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid
AC1L22FK
AC1Q63H0
Agucort
Agucort (TN)
BIDD:GT0426
BRD-K76011241-045-01-5
C08092
CHEBI:7798
CHEMBL1229
CID65028
D08306
DB00198
Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate
Ethyl (5S,3R,4R)-4-(acetylamino)-5-amino-3-(ethylpropoxy)cyclohex-1-enecarboxylate
FT-0082384
 
GS 4104
GS-4104
GS4104
HMS2090C11
HSDB 7433
LS-57422
MolPort-005-933-026
NCGC00178698-01
Oseltamivir
Oseltamivir (INN)
Oseltamivir [INN:BAN]
Oseltamivir phosphate
Oseltamivirum
Ro-64-0796
Ro-640796
Tamiflu
Tamiflu (*Phosphate salt 1:1*)
Tamiflu-Free
Tamvir
UNII-20O93L6F9H
ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate
ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate
oseltamivir
oseltamivirum
5
FormaldehydeexperimentalPhase 2, Phase 3, Phase 17350-00-0712
Synonyms:
Aldeide formica
Fannoform
Formaldehyde
Formalina
Formaline
Formalith
Formic aldehyde
Formol
 
Methaldehyde
Methanal
Methyl aldehyde
Methylene glycol
Methylene oxide
Oxomethane
Oxomethylene
Oxymethylene
Paraform
Paraformaldehyde
6AgglutininsPhase 3, Phase 1, Phase 230
7Anti-Infective AgentsPhase 2, Phase 3, Phase 117220
8Antiviral AgentsPhase 2, Phase 3, Phase 18071
9HemagglutininsPhase 3, Phase 2, Phase 1111
10Pharmaceutical SolutionsPhase 3, Phase 1, Phase 27004
11Heptavalent Pneumococcal Conjugate VaccinePhase 3440
12ImmunoglobulinsPhase 3, Phase 2, Phase 14477
13Gastrointestinal AgentsPhase 3, Phase 1, Phase 26401
14CatharticsPhase 3344
15Immunosuppressive AgentsPhase 310422
16
LactitolPhase 3, Phase 2, Phase 1320585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
17AntibodiesPhase 3, Phase 2, Phase 14477
18MF59 oil emulsionPhase 3, Phase 2, Phase 196
19LaxativesPhase 3344
20
Zanamivirapproved, investigationalPhase 2, Phase 120139110-80-860855
Synonyms:
(2R,3R,4S)-3-(acetylamino)-4-Carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
(2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
139110-80-8
1a4g
2qwe
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid
4-Guanidino-NeueAc2en
4-Guanidino-neu5ac2en
5-(acetylamino)-2,6-Anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid
5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid
5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid
5-acetamido-2,6-Anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid
AC1L1U2A
BIDD:GT0349
C08095
CHEBI:50663
CHEMBL222813
CID60855
 
CPD000469215
D00902
DB00558
GANA
GG-167
GG167
GNA
GR-121167X
GR121167X
MODIFIED SIALIC ACID
Modified sialic acid
Relenza
Relenza (TN)
SAM001246788
ZANAMIVIR
ZMR
Zanamavir
Zanamivir (USAN/INN)
Zanamivir hydrate
zanamivir
21
DopamineapprovedPhase 2308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
22
AmantadineapprovedPhase 265768-94-52130
Synonyms:
1-Adamantamine
1-Adamantanamine
1-Adamantanamine (8CI)
1-Adamantylamine
1-Aminoadamantane
1-Aminotricyclo(3.3.1.1(sup 3,7))decane
1-adamantanamine
1-adamantylamine
1-aminoadamantane
138576_ALDRICH
665-66-7 (hydrochloride)
768-94-5
AB00514655
AC-11992
AC1L1CZI
AC1Q4UAF
AC1Q5396
ADAMANTANE,1-AMINO
AKOS000113994
AKOS000119324
Adamantamine
Adamantanamine
Adamantylamine
Amant
Amantadina
Amantadina [INN-Spanish]
Amantadine
Amantadine (INN)
Amantadine Base
Amantadine HCL
Amantadine Hydrochloride
Amantadine [INN:BAN]
Amantadine hydrochloride
Amantadine sulfate
Amantadinum
Amantadinum [INN-Latin]
Amantidine
Ambap768-94-5
Aminoadamantane
BIA4304
BIDD:GT0757
BPBio1_000368
BRN 2204333
BSPBio_000334
BSPBio_001570
BSPBio_001822
Bio-0821
C06818
C10H17N
CHEBI:2618
CHEMBL660
CID2130
D07441
DB00915
DivK1c_000815
EINECS 212-201-2
Endantadine
Gen-Amantadine
HMS1791O12
HMS1989O12
HSDB 3202
I14-1101
IDI1_000815
InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H
 
KBio1_000815
KBio2_000390
KBio2_002958
KBio2_005526
KBio3_001322
KBioGR_000548
KBioSS_000390
L000868
LS-157049
Lopac-A-1260
Lopac0_000004
Mantadine
MolPort-001-661-700
MolPort-001-760-587
MolPort-001-791-102
NCGC00015036-01
NCGC00015036-07
NCGC00162039-01
NCGC00162039-02
NCGC00162039-03
NCGC00162039-04
NCGC00179597-01
NCIOpen2_001059
NINDS_000815
NSC 341865
NSC341865
NSC83653
OR14310
Oprea1_248648
Pk-merz
Prestwick0_000407
Prestwick1_000407
Prestwick2_000407
Prestwick3_000407
SPBio_000002
SPBio_002273
STK298781
Spectrum2_000081
Spectrum3_000291
Spectrum4_000134
Spectrum5_000772
Spectrum_000030
Symadine
Symmetrel
TCMDC-125869
TL8005280
Tricyclo(3.3.1.1(3,7))-decan-1-amine
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine
Tricyclo(3.3.1.1(sup 3.7))decan-1-amine
Tricyclo(3.3.1.13,7)decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-ylamine
Tricyclo[3.3.1.1(3,7)]decane-1-amine
Tricyclo[3.3.1.1(sup3,7)]decan-1-amine
Tricyclo[3.3.1.1^3,7]decan-1-amine
UNII-BF4C9Z1J53
Viregyt
Virosol
WLN: L66 B6 A B- C 1B ITJ BZ
Wiregyt
adamantan-1-amine
adamantan-1-ylamine
amantadine
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
tricyclo[3.3.1.1(3,7)]decane-1-amine
tricyclo[3.3.1.1~3,7~]decan-1-amine
23AntacidsPhase 1, Phase 21453
24Adjuvants, ImmunologicPhase 1, Phase 21783
25Anti-Ulcer AgentsPhase 1, Phase 21453
26Aluminum sulfatePhase 279
27Dopamine AgentsPhase 23084
28Neurotransmitter AgentsPhase 214795
29Peripheral Nervous System AgentsPhase 218510
30Antiparkinson AgentsPhase 21312
31AnalgesicsPhase 29358
32Analgesics, Non-NarcoticPhase 25184
33
ProbenecidapprovedPhase 12757-66-94911
Synonyms:
4-((Dipropylamino)sulfonyl)benzoic acid
4-(Di-N-propylsulfamoyl)benzoesaeure
4-(Di-n-propylsulfamoyl)benzoesaeure
4-(Dipropylsulfamoyl)benzoic acid
4-(N,N-Dipropylsulfamoyl)benzoesaeure
4-[(dipropylamino)sulfonyl]benzoic acid
57-66-9
AB00052080
AC-2023
AC1L1J86
AC1Q2XQM
AC1Q2XQN
AI3-50078
AKOS000165123
Apurina
BIDD:GT0626
BIDD:PXR0092
BPBio1_000643
BRD-K95237249-001-05-9
BRN 2815775
BSPBio_000583
BSPBio_002227
Bencid
Benecid
Benemid
Benemid (TN)
Benemide
Benuryl
Biokanol Brand of Probenecid
C07372
C13H19NO4S
CAS-57-66-9
CCRIS 3643
CHEBI:177474
CHEMBL897
CID4911
CPD000058280
Col-BENEMID
Col-Probenecid
ColBenemid (co mponent of)
ColBenemid (component of)
Colbenemid
D00475
D011339
DB01032
DivK1c_000056
EINECS 200-344-3
HMS1569N05
HMS1920J22
HMS2092C03
HMS500C18
HSDB 3387
I01-1905
ICN Brand of Probenecid
IDI1_000056
IDIS Brand of Probenecid
KBio1_000056
KBio2_001314
KBio2_003882
KBio2_006450
KBio3_001727
KBioGR_000971
KBioSS_001314
LS-33
MLS000028496
MLS001076472
Major Brand of Probenecid
Martec Brand of Probenecid
Merck Brand of Probenecid
MolPort-000-145-935
NCGC00016251-01
NCGC00016251-02
NCGC00023829-03
 
NCGC00023829-04
NCGC00023829-05
NCGC00023829-06
NCI-C56097
NINDS_000056
NSC 18786
NSC18786
Ophthalmic Brand of Probenecid
Oprea1_416955
P-(Dipropylsulfamoyl)benzoic acid
P8761_SIGMA
Panuric
Parabenem
Parmed Brand of Probenecid
Polycillin-BRB
Polycillin-PRB
Polycillin-PRB (component of)
Prestwick0_000542
Prestwick1_000542
Prestwick2_000542
Prestwick3_000542
Prestwick_809
Pro-Cid
Probalan
Probampacin
Probecid
Proben
Proben-C
Probenecid
Probenecid (JP15/USP/INN)
Probenecid Acid
Probenecid Major Brand
Probenecid Martec Brand
Probenecid Parmed Brand
Probenecid Weimer
Probenecid Zenith Brand
Probenecid [INN:BAN:JAN]
Probenecid acid
Probenecida
Probenecida [INN-Spanish]
Probenecide
Probenecide [INN-French]
Probenecidum
Probenecidum [INN-Latin]
Probenemid
Probenicid
Probenid
Probexin
Prolongine
Robenecid
SAM002554923
SBB028597
SMR000058280
SPBio_001327
SPBio_002504
SPECTRUM1500502
Spectrum2_001294
Spectrum3_000554
Spectrum4_000486
Spectrum5_001419
Spectrum_000834
Sulprin
Synergid R
Tubophan
UNII-PO572Z7917
Uricosid
Urocid
Valdecasas Brand of Probenecid
WLN: QVR DSWN3&3
Zenith Brand of Probenecid
p-(Dipropylsulfamoyl)benzoic acid
p-(Dipropylsulfamyl)benzoic acid
p-[Dipropylsulfamoyl]benzoic acid
probenecid
probenicid
34
Peramivirapproved, investigationalPhase 115229614-55-5151164
Synonyms:
(1S,2S,3S,4R)-3-(1-acetamido-2-ethylbutyl)-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
(1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
1A5BB290
229614-55-5
229614-56-6
3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic acid
3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID
330600-85-6
AC1L45SI
AC1L4BWX
BCX 1812
BCX-1812
BCX1812
BCZ
 
CHEBI:292932
CHEBI:41095
CHEMBL139367
CHEMBL332608
CID151164
CID154234
PeramiFlu
Peramivir
RWJ 270201
RWJ-270201
RWJ270201
Rapiacta
Rapivab
S-021812
UNII-QW7Y7ZR15U
35
Inulinapproved, nutraceuticalPhase 1959005-80-524763
Synonyms:
(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethy
189444-25-5
887747-94-6
AC1L2NNM
AI3-19506
CID24763
DB00638
 
EINECS 232-684-3
INULIN
Inulin USP 27
Inulin [BAN]
Inulin and sodium chloride
Inulin from Jerusalem artichokes
LS-186416
LS-187349
36Antibiotics, AntitubercularPhase 15971
37Anti-Bacterial AgentsPhase 19140
38Antirheumatic AgentsPhase 18496

Interventional clinical trials:

(show top 50)    (show all 205)
idNameStatusNCT IDPhase
1Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years OldCompletedNCT01730378Phase 4
2The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza VaccineCompletedNCT02269852Phase 4
3Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult PatientsRecruitingNCT01017172Phase 4
4Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of AgeCompletedNCT01310413Phase 3
5H5N1 Vaccine Study in Japanese AdultsCompletedNCT01382329Phase 2, Phase 3
6Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) ExposureCompletedNCT01788228Phase 3
7Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)CompletedNCT00462215Phase 3
8Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza VaccineCompletedNCT02107807Phase 3
9Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk GroupsCompletedNCT00711295Phase 3
10Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 YearsCompletedNCT00616928Phase 3
11Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly SubjectsCompletedNCT00434733Phase 3
12Japanese Pediatric H5N1 Vaccine StudyCompletedNCT01911754Phase 3
13H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and OlderCompletedNCT01774032Phase 3
14Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four DifferentCompletedNCT00848029Phase 3
15Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical ConditionsCompletedNCT02091908Phase 3
16A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in ChildrenCompletedNCT01379937Phase 3
17Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and AboveCompletedNCT00319098Phase 3
18Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly SubjectsCompletedNCT00841763Phase 3
19Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult VolunteersCompletedNCT01987011Phase 3
20Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination SchedulesCompletedNCT00652743Phase 3
21Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic DiseasesCompletedNCT00519064Phase 3
22Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsCompletedNCT00806195Phase 3
23A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 MonthsCompletedNCT01000311Phase 3
24A Safety and Immunogenicity Study of IVACFLU-A/H5N1Not yet recruitingNCT02612909Phase 2, Phase 3
25Oseltamivir for Influenza Lower Respiratory Tract Infection in Children Under OneWithdrawnNCT01546935Phase 2, Phase 3
26Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)CompletedNCT01910519Phase 2
27Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy AdultsCompletedNCT01776541Phase 2
28Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 YearsCompletedNCT00537524Phase 2
29A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64CompletedNCT00695669Phase 2
30Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in ChildrenCompletedNCT01776554Phase 2
31Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly SubjectsCompletedNCT01766921Phase 2
32Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly SubjectsCompletedNCT00914771Phase 2
33Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)CompletedNCT00812019Phase 1, Phase 2
34H7N9 Mix and Match With AS03 and MF59 in Healthy AdultsCompletedNCT01942265Phase 2
35Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza VaccineCompletedNCT00561184Phase 2
36Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza VaccinesCompletedNCT00478816Phase 2
37H7N9 Mix and Match With MF59 in Healthy AdultsCompletedNCT01938742Phase 2
38Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in AdultsCompletedNCT01416571Phase 2
39Inactivated Influenza A/H5N1 Vaccine in the ElderlyCompletedNCT00230750Phase 1, Phase 2
40A/H5N1 Vaccine in Healthy Children Aged 2-9 YearsCompletedNCT00133536Phase 1, Phase 2
41Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 YearsCompletedNCT00719043Phase 2
42Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young AdultsCompletedNCT00980447Phase 2
43Safety, Reactogenicity and Immunogenicity of an H5N1 VLPCompletedNCT00519389Phase 1, Phase 2
44H5 Adult - Chiron Study of Bird Flu VaccineCompletedNCT00280033Phase 1, Phase 2
45Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and AboveCompletedNCT00620815Phase 2
46A/H5N1/LT Dose Ranging StudyCompletedNCT00908687Phase 2
47Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in AdultsCompletedNCT00382187Phase 2
48H5 Vaccine Alone or With Aluminum Hydroxide in Elderly AdultsCompletedNCT00294099Phase 1, Phase 2
49H5N1 (Clade 2) Vaccination of Adults and ElderlyCompletedNCT00680069Phase 1, Phase 2
50Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed AdultsCompletedNCT01195038Phase 2

Search NIH Clinical Center for Avian Influenza


Cochrane evidence based reviews: influenza in birds

Genetic Tests for Avian Influenza

About this section

Anatomical Context for Avian Influenza

About this section

MalaCards organs/tissues related to Avian Influenza:

33
Lung, Testes, Breast, Heart, Prostate, B cells, Bone

FMA organs/tissues related to Avian Influenza:

16
Respiratory tract of humans

Animal Models for Avian Influenza or affiliated genes

About this section

MGI Mouse Phenotypes related to Avian Influenza:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053819.1CRK, DDX58, FURIN, PCSK5, PCSK6, SCRIB
2MP:00053888.9CRK, NEU1, PCSK5, PCSK6, SCRIB, SFTPD
3MP:00107687.5CRK, CXCL10, DDX58, FURIN, NEU1, PCSK5

Publications for Avian Influenza

About this section

Articles related to Avian Influenza:

(show top 50)    (show all 672)
idTitleAuthorsYear
1
Risk Reduction Modeling of High Pathogenicity Avian Influenza Virus Titers in Nonpasteurized Liquid Egg Obtained from Infected but Undetected Chicken Flocks. (25867713)
2015
2
Prevalence of Newcastle disease virus and infectious bronchitis virus in avian influenza negative birds from live bird markets and backyard and commercial farms in Ivory-Coast. (26412525)
2015
3
Avian influenza H9N2 seroprevalence among pig population and pig farm staff in Shandong, China. (25886647)
2015
4
Quantitative Estimation of the Number of Contaminated Hatching Eggs Released from an Infected, Undetected Turkey Breeder Hen Flock During a Highly Pathogenic Avian Influenza Outbreak. (26478153)
2015
5
Amino acid residues at positions 222 and 227 of the hemagglutinin together with the neuraminidase determine binding of H5 avian influenza viruses to sialyl Lewis X. (26542967)
2015
6
Avian influenza H9N2 seroprevalence among swine farm residents in China. (24390939)
2014
7
Contemporary avian influenza a virus subtype h1, h6, h7, h10, and h15 hemagglutinin genes encode a Mammalian virulence factor similar to the 1918 pandemic virus h1 hemagglutinin. (25406382)
2014
8
Migratory birds reinforce local circulation of avian influenza viruses. (25391154)
2014
9
Exposure to avian influenza H7N9 in farms and wet markets. (23664058)
2013
10
Pathogenicity of an H5N1 highly pathogenic avian influenza virus isolated in the 2010-2011 winter in Japan to mandarin ducks. (23318574)
2013
11
Seroprevalence of antibodies to highly pathogenic avian influenza A (H5N1) virus among close contacts exposed to H5N1 cases, China, 2005-2008. (23967241)
2013
12
Characterisation and haemagglutinin gene epitope mapping of a variant strain of H5N1 subtype avian influenza virus. (23265247)
2013
13
Immune responses of chickens inoculated with recombinant Lactobacillus expressing the haemagglutinin of the avian influenza virus. (23937220)
2013
14
Surveillance for avian influenza A(H7N9), Beijing, China, 2013. (24274700)
2013
15
Differences in the detection of highly pathogenic avian influenza H5N1 virus in feather samples from 4-week-old and 24-week-old infected Pekin ducks (Anas platyrhynchos var. domestica). (23608476)
2013
16
Development and optimization of a biopreparedness protocol for extracting and detecting avian influenza virus in broiler chicken meat. (23971811)
2013
17
Estimation of the sensitivity of the surveillance system for avian influenza in the western region of Cuba. (23564591)
2013
18
Avirulent Marek's disease virus type 1 strain 814 vectored vaccine expressing avian influenza (AI) virus H5 haemagglutinin induced better protection than turkey herpesvirus vectored AI vaccine. (23301062)
2013
19
Amaryllidaceae alkaloids inhibit nuclear-to-cytoplasmic export of ribonucleoprotein (RNP) complex of highly pathogenic avian influenza virus H5N1. (23136954)
2013
20
H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus. (23988294)
2013
21
Discover binding pathways using the sliding binding-box docking approach: application to binding pathways of oseltamivir to avian influenza H5N1 neuraminidase. (23979194)
2013
22
Preliminary Report: Epidemiology of the Avian Influenza A (H7N9) Outbreak in China. (23614499)
2013
23
Age-specific and sex-specific morbidity and mortality from avian influenza A(H7N9). (24091087)
2013
24
Highly pathogenic avian influenza A(H5N1) mutants transmissible by air are susceptible to human and animal neutralizing antibodies. (23868877)
2013
25
Experimental infection of non-human primates with avian influenza virus (H9N2). (23665767)
2013
26
Full Genome Sequence of an Avian Influenza H5N1 Virus Isolated from the Environment in Hunan Province, China. (23682135)
2013
27
Goose Toll-like receptor 7 (TLR7), myeloid differentiation factor 88 (MyD88) and antiviral molecules involved in anti-H5N1 highly pathogenic avian influenza virus response. (23481654)
2013
28
Avian influenza: mixed infections and missing viruses. (23921843)
2013
29
Baculovirus vector as an avian influenza vaccine: hemagglutinin expression and presentation augment the vaccine immunogenicity. (23313887)
2013
30
Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. (23526211)
2013
312013
32
Evaluation of phenotypic markers in full genome sequences of avian influenza isolates from California. (23891310)
2013
33
Qualitative dynamics of lowly- and highly-pathogenic avian influenza strains. (23485554)
2013
34
Descriptive Results of a Prospective Cohort Study of Avian Influenza in the Mekong River Delta of Viet Nam. (23331425)
2013
35
Contribution of the NS1 Gene of H7 Avian Influenza Virus Strains to Pathogenicity in Chickens. (24236854)
2013
36
Avian Influenza A(H7N9) Virus Screening in Patients with Fever and Flu-Like Symptoms in a Tertiary Hospital in an Area with Confirmed Cases. (24367529)
2013
37
Subtype diversity and reassortment potential for co-circulating avian influenza viruses at a diversity hot spot. (24164627)
2013
38
Risk factors for avian influenza and Newcastle disease in smallholder farming systems, Madagascar highlands. (22130311)
2012
39
The pathogenesis of low pathogenic avian influenza in mallards. (23402122)
2012
40
Satellite tracking on the flyways of brown-headed gulls and their potential role in the spread of highly pathogenic avian influenza H5N1 virus. (23209623)
2012
41
Transmissibility of the highly pathogenic avian influenza virus, subtype H5N1 in domestic poultry: a spatio-temporal estimation at the global scale. (23242687)
2012
42
Complete genome sequence of an H10N5 avian influenza virus isolated from pigs in central China. (23166264)
2012
43
Associations of chicken Mx1 polymorphism with antiviral responses in avian influenza virus infected embryos and broilers. (23155008)
2012
44
Surveillance for avian influenza and Newcastle disease in backyard poultry flocks in CA'te d'Ivoire, 2007-2009. (23520736)
2012
45
Avian influenza virus and Newcastle disease virus (NDV) surveillance in commercial breeding farm in China and the characterization of Class I NDV isolates. (20133090)
2010
46
Heterosubtypic T-cell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza. (19453462)
2008
47
Avian influenza virus A/HK/483/97(H5N1) NS1 protein induces apoptosis in human airway epithelial cells. (18199656)
2008
48
Insufficient perforin expression in CD8+ T cells in response to hemagglutinin from avian influenza (H5N1) virus. (16585542)
2006
49
p38 mitogen-activated protein kinase-dependent hyperinduction of tumor necrosis factor alpha expression in response to avian influenza virus H5N1. (16051807)
2005
50

Variations for Avian Influenza

About this section

Expression for genes affiliated with Avian Influenza

About this section
Search GEO for disease gene expression data for Avian Influenza.

Pathways for genes affiliated with Avian Influenza

About this section

Pathways related to Avian Influenza according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.7FURIN, PCSK5, PCSK6
2
Show member pathways
7.8CXCL10, DDX58, FURIN, IFNA1, TMPRSS13, TNFSF10

GO Terms for genes affiliated with Avian Influenza

About this section

Biological processes related to Avian Influenza according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1signal peptide processingGO:000646510.3FURIN, PCSK5
2nerve growth factor processingGO:003245510.2FURIN, PCSK5
3protein processingGO:001648510.0FURIN, PCSK5
4peptide hormone processingGO:001648610.0FURIN, PCSK5, PCSK6
5cell-cell signalingGO:00072679.4CXCL10, PCSK5, TNFSF10

Sources for Avian Influenza

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet